This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have included platinum (no more than four total lines of prior therapy), with or without bevacizumab, whose cancer has recurred within six months of the most recent platinum-based chemotherapy. All eligible subjects will receive VAL 083 i.v. in a once weekly cycle until disease progression, development of other unacceptable toxicity, death, withdrawal of consent, loss to follow-up, or Sponsor ending the study, whichever occurs first.

开始日期2021-03-01

申办/合作机构

Kintara Therapeutics, Inc.

NCT03970447 / Recruiting临床2/3期IIT

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

开始日期2019-07-30

申办/合作机构

朴莱雷斯集团

[+5]

100 项与去水卫矛醇相关的临床结果

登录后查看更多信息

100 项与去水卫矛醇相关的转化医学

登录后查看更多信息

100 项与去水卫矛醇相关的专利（医药）

登录后查看更多信息

298

项与去水卫矛醇相关的文献（医药）

2024-02-01·Food chemistry

The cross-linking ability of dialdo-galactose in food processing condition

Article

作者: Xue, Changhu ; Chen, Kai ; Liu, Yonghao ; Xu, Ying ; Yu, Jiaqi ; Sun, Xun ; Cao, Honghua

Cross-linking is a popular strategy to tailor the mechanical profile of foods and materials. Dialdo-galactose (DAG) is a hetero-sugar bearing two aldehyde groups that could potentially cross-link amino-group rich systems. In this study, we proved even in undesirable Maillard reaction condition, DAG is a very reactive Maillard substrate that could effectively cross-link all the tested foods, enhance their mechanical strength, and generate brown pigments during cross-linking. In particular, DAG treated sea cucumber exhibited good stability against heat-induced deterioration. In addition, DAG treated collagen sausage casing was more elastic and flexible then glutaraldehyde (GA) treated ones. DAG also outperformed GA in generating stronger chitosan hydrogels with higher G', and the DAG cross-linked chitosan film was more robust against acid-catalyzed decompositions. These results have not only confirmed DAG's cross-linking ability in food processing condition, but also provided useful information for the development of new food cross-linking agents based on oxidized saccharides.

2023-11-01·Molecular and cellular endocrinology

Desacylghrelin modulates GHS-R1 receptor expression and cell differentiation in placental BeWo cells

Article

作者: Leon-Verdin, Ma Guadalupe ; Jaramillo-Narvaez, Maria-de-la-Luz ; Coria-Caballero, Vanessa ; Lazo-de-la-Vega-Monroy, Maria-Luisa ; Barbosa-Sabanero, Gloria ; Martinez, Federico

BACKGROUND:

and purpose: Ghrelin is the endogenous ligand of the growth hormone secretagogue receptor (GHS-R1). Ghrelin, and GHS-R1, may have a role in placental growth and function, and its unacylated form desacylghrelin (DAG) could be involved in fetal growth. Nevertheless, the effects of DAG on placental function, and the receptor involved in its actions, remain to be determined. We aimed to investigate the effect of DAG in placental BeWo cells viability, proliferation, differentiation, and GSH-R1 expression.

METHODS:

BeWo cells, a human trophoblast cell line, was cultured with 3 nM DAG during 12, 24, 48, and 72 h. Cell viability, proliferation, differentiation (assessed by human Chorionic Gonadotropin quantification), and GSH-R1 expression were analyzed. To evaluate the mechanism of DAG effect on GSH-R1, 30 nM receptor antagonist ([D-Lys3]-GHRP-6) was added alone or in combination with 3 nM DAG during 12 h and 24 h.

RESULTS:

DAG has no effect on cell proliferation or viability, but it has an inhibitory effect on cell differentiation. DAG had a stimulatory effect on GSH-R1 expression at 12 and 24 h (p = 0.029 and p = 0.025, respectively). On the contrary, culture with 48 h DAG inhibits GSH-R1 expression compared to the control (p = 0.005), while GSH-R1 antagonist inhibited the effect of DAG on GSH-R1 expression. DAG also reduces intracellular (p = 0.020) and secreted (p = 0.011) hCG concentration in BeWo cells.

CONCLUSION:

DAG increases GHS-R1 expression, potentially mediated through GHS-R1 itself. DAG may also inhibit placental BeWo cell differentiation, suggesting a possible role of DAG in placental and fetal physiology.

2023-10-01·iScience

Addition of exogenous diacylglycerol enhances Wnt/β-catenin signaling through stimulation of macropinocytosis

Article

作者: Ozhan, Gunes ; De Robertis, Edward M ; Dayrit, Alex ; Monka, Julia C ; Tejeda-Munoz, Nydia ; Azbazdar, Yagmur ; Binder, Grace

Activation of Wnt signaling triggers macropinocytosis and drives many tumors. We now report that the exogenous addition of the second messenger lipid sn-1,2 DAG to the culture medium rapidly induces macropinocytosis. This is accompanied by potentiation of the effects of added Wnt3a recombinant protein or the glycogen synthase kinase 3 (GSK3) inhibitor lithium chloride (LiCl, which mimics Wnt signaling) in luciferase transcriptional reporter assays. In a colorectal carcinoma cell line in which mutation of adenomatous polyposis coli (APC) causes constitutive Wnt signaling, DAG addition increased levels of nuclear β-catenin, and this increase was partially inhibited by an inhibitor of macropinocytosis. DAG also expanded multivesicular bodies marked by the tetraspan protein CD63. In an in vivo situation, microinjection of DAG induced Wnt-like twinned body axes when co-injected with small amounts of LiCl into Xenopus embryos. These results suggest that the DAG second messenger plays a role in Wnt-driven cancer progression.

项与去水卫矛醇相关的新闻（医药）

2024-02-14

·PRNewswire

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2023, and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced the initiation of an open label 15-patient study in cutaneous metastatic breast cancer (CMBC) patients which is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate (bORR) (complete response or partial response) of the target treatment fields at any time from treatment up to, and including, week 24. The majority of the costs to run this study will be covered by the $2.0 million Small Business Innovation Research (SBIR) grant Kintara was awarded from the National Institutes of Health (NIH). (February 2024) Announced that Kintara's Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged Ladenburg Thalmann & Co. Inc. to act as financial advisor for this process. (December 2023) Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. As a result, Kintara terminated the development of VAL-083 and turned its focus to its REM-001 program. (October 2023) "We are pleased to have recently initiated our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "We have strengthened our balance sheet primarily with net proceeds from our at-the-market (ATM) facility and aggressive cost-cutting efforts. We continue to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2023 As of December 31, 2023, Kintara had cash and cash equivalents of approximately $0.7 million. From January 1, 2024, to February 12, 2024, the Company has received net proceeds of approximately $6.1 million from the sale of common stock, primarily from its ATM facility. For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share, compared to a net loss of approximately $3.5 million, or $2.10 per share, for the three months ended December 31, 2022. The decreased net loss for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was largely attributed to lower research and development expenses which was primarily due to lower clinical development costs. General and administrative costs were also lower during the same period primarily due to a reduction in personnel. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and LinkedIn. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's REM-001 15-patient clinical trial in CMBC patients; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

财报临床3期放射疗法

2023-11-13

·PRNewswire

Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a wide range of strategic options aimed at potentially maximizing shareholder value. (October 2023) Awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical development of REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent for the treatment of cutaneous metastatic breast cancer (CMBC). (June 2023) "We are looking forward to enrolling the first patient in our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "The majority of study expenses will be covered by the $2 million National Institutes of Health grant we were awarded to support the further development of REM-001. We have undertaken efforts to significantly cut costs and are continuing to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 FIRST QUARTER ENDED SEPTEMBER 30, 2023 As of September 30, 2023, Kintara had cash and cash equivalents of approximately $0.2 million. In November 2023, the Company has received net proceeds of approximately 1.0 million from the sale of common stock, primarily from its at-the-market (ATM) facility. For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022. The decreased net losses for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was largely due to lower research and development expenses, primarily lower clinical development costs. General and administrative costs were also lower during the same period primarily due to reduced level of staffing. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara develops therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and Linkedin. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

财报放射疗法

2023-10-31

·PRNewswire

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

- VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities - SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a wide range of strategic options aimed at potentially maximizing shareholder value. "Glioblastoma represents a high unmet medical need, and patients with this disease have very few treatment options," said Robert E. Hoffman, President and Chief Executive Officer of Kintara. "We are very disappointed that the VAL-083 GBM AGILE Study preliminary results do not support continued development efforts to give patients additional treatment options. We sincerely appreciate the exceptional support from patients and their families as well as patient advocates, physicians and our employees who have been committed to the rigorous study of VAL-083. As we shift priorities, we look forward to enrolling our first patient in our 15-patient study of REM-001 in cutaneous metastatic breast cancer (CMBC). Additionally, we will conduct a thorough review of potential strategic opportunities for us to maximize shareholder value in the Company." "GBM AGILE is a rigorous mechanism for us to efficiently evaluate investigational drugs in a well-controlled, randomized setting," said Meredith Buxton, CEO and President of Global Coalition of Adaptive Research, Sponsor of GBM AGILE. "While we are disappointed that the preliminary results for VAL-083 did not show benefit over standard of care, GBM AGILE is operating as designed and we await final data for VAL-083 in 2024 to better understand if there are possible pathways for further development." All development activities and related costs for VAL-083 will be suspended while the Company awaits the full dataset from the GBM AGILE Study which is expected at the end of the first quarter/beginning of second quarter of calendar year 2024. At such time Kintara will analyze the full results as it seeks to maximize the value of the VAL-083 asset. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of calendar year 2023. The Company was recently awarded a $2 million grant from the National Institutes of Health (NIH) which is expected to cover the majority of the cost to run the CMBC study. In November 2022, the United States Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of patients with CMBC. REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs and reduced development risk. Kintara's focus is the development of REM-001 as a treatment for CMBC. For more information, please visit or follow us on X (formerly Twitter) at @Kintara_Thera, Facebook and LinkedIn. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials, the topline results of the GBM AGILE Study and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

快速通道临床结果放射疗法

100 项与去水卫矛醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB12873

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺癌	中国	广西梧州制药（集团）股份有限公司	2020-09-13
费城染色体阳性慢性粒细胞白血病	中国	广西梧州制药（集团）股份有限公司	2020-09-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胶质母细胞瘤	临床3期	澳大利亚	Kintara Therapeutics, Inc.	2019-07-30
胶质母细胞瘤	临床3期	德国	Kintara Therapeutics, Inc.	2019-07-30
多形性胶质母细胞瘤	临床3期	美国	Kintara Therapeutics, Inc.	2017-10-27
复发性胶质母细胞瘤	临床3期	美国	Kintara Therapeutics, Inc.	2017-10-27
卵巢癌	临床2期	美国	Kintara Therapeutics, Inc.	2021-03-01
复发性铂耐药性卵巢癌	临床2期	美国	Kintara Therapeutics, Inc.	2021-03-01
胶质瘤	临床2期	中国	Kintara Therapeutics, Inc.	2017-12-17
复发性恶性胶质瘤	临床2期	美国	Kintara Therapeutics, Inc.	2011-10-01
弥漫内生性脑桥神经胶质瘤	临床前	美国	Kintara Therapeutics, Inc.	2019-04-21
髓母细胞瘤	临床前	美国	Kintara Therapeutics, Inc.	2016-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03138629 (AACR2023) 人工标引	N/A	复发性胶质母细胞瘤 unmethylated MGMT promoter \| IDH wild type \| MSH6 mutation ... 更多	24	VAL-083 30mg/m2 ± Bevacizumab	衊艱鹹膚蓋膚獵膚餘醖(淵鏇鹹膚齋糧鹽顧廠艱) = VAL-083 was well tolerated and the main adverse events were consistent with prior experience, i.e., thrombocytopenia and neutropenia. 鏇夢製繭鏇廠鹽餘製衊 (範糧遞範蓋鑰鑰積獵窪 )	积极	2023-04-14
NCT03138629 (AACR2023) 人工标引	N/A		24	VAL-083 30mg/m2 ± Bevacizumab (Patients without multifocal disease)		积极	2023-04-14
NCT02717962 (PRNewswire) 人工标引	临床2期	胶质母细胞瘤	89	VAL-083 (40 mg/m2/day)	範憲築獵淵憲膚鏇衊糧(鬱鏇淵願餘糧觸蓋鹹築) = 餘壓積網衊窪衊簾築壓獵淵醖餘獵憲壓夢齋齋 (鬱鹹齋蓋蓋觸範壓醖襯, 6.1 ~ 9.0)	积极	2021-07-01
NCT02717962 (PRNewswire) 人工标引	临床2期	胶质母细胞瘤	89	VAL-083 (receiving the treatment dose of 30 mg/m2/day on days 1, 2 and 3 of a 21-day cycle)	範憲築獵淵憲膚鏇衊糧(鬱鏇淵願餘糧觸蓋鹹築) = 製憲鹹廠簾艱餘製蓋積獵淵醖餘獵憲壓夢齋齋 (鬱鹹齋蓋蓋觸範壓醖襯, 5.9 ~ 9.9) 更多	积极	2021-07-01
NCT01478178 (DLM-10-001, ASCO2018)	临床1/2期	胶质母细胞瘤	45	Clinically active dose of VAL-083	鬱艱鬱鬱範艱範鏇選鹽(窪積鹽廠鬱獵膚網鬱願) = 糧夢襯構積鏇繭範築網艱構選醖淵蓋壓鑰壓顧 (淵夢鹹夢憲餘醖觸繭遞, 3.1 ~ 9.6)	积极	2018-06-01
NCT01478178 (DLM-10-001, ASCO2018)	临床1/2期	胶质母细胞瘤	45	Inactive dose of VAL-083	鬱艱鬱鬱範艱範鏇選鹽(窪積鹽廠鬱獵膚網鬱願) = 遞襯範範艱齋鑰鬱簾網艱構選醖淵蓋壓鑰壓顧 (淵夢鹹夢憲餘醖觸繭遞 )	积极	2018-06-01
NCT01478178 (AACR2016)	临床1/2期	复发性胶质母细胞瘤	55	VAL-083	餘獵醖範構鬱鏇廠鏇觸(糧齋積鹹夢夢糧餘選糧) = Observed myelosuppression is mild, with the exception of 1 patient previously treated with CCNU who developed grade 4 thrombocytopenia 網簾網窪糧範製鬱選鑰 (鬱醖餘觸顧鏇積顧齋憲 ) 更多	积极	2016-07-15
NCT01478178 (ASCO2016)	临床1/2期	复发性胶质母细胞瘤	55	VAL-083	遞餘餘網觸製窪構憲構(遞築鬱鹽醖憲遞範範衊) = 窪構衊製鏇鹽糧鏇憲齋壓餘膚窪衊膚築觸憲構 (選衊餘蓋構壓積築鹹糧 )	积极	2016-05-20
NCT01478178 (AACR2014)	临床1/2期	胶质母细胞瘤	-	VAL-083	鹹鬱獵鏇鬱鹽糧艱襯廠(壓廠繭顧顧膚繭獵獵鏇) = cohorts 1 through 4 (10 mg/m2) have completed the trial successfully with no drug-related serious adverse events (SAEs) 窪鬱簾簾艱觸廠範鑰鑰 (衊鏇獵鏇獵觸鏇糧鑰選 )	-	2014-10-01
NCT01478178 (ASCO2014)	临床1/2期	复发性恶性胶质瘤	55	Dianhydrogalactitol (VAL-083)	壓淵齋網選願顧鹹顧鑰(醖積願醖選艱餘觸廠鹽) = 齋夢憲襯鹽鹽糧顧鑰簾餘衊衊網鑰顧壓餘窪顧 (遞構遞觸鏇廠鑰齋鬱鏇 )	-	2014-05-20
NCT01478178 (ASCO2013)	临床1/2期	复发性恶性胶质瘤 \| 脑癌	55	VAL-083	糧鏇齋網願醖襯顧鏇鹹(網願獵製齋鹽網顧範範) = 齋遞積鹹鑰膚鏇選願顧願鬱繭顧憲膚醖淵築鬱 (鹹蓋窪憲簾夢廠網範衊 )	-	2013-05-20